Anjan Talukdar, MD
Vascular Surgery · Omaha, NENPI 1346479706
Payments from drug & device makers
Across 456 payments — averaging $55.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$5K
- Endologix LLC$4K
- Penumbra, Inc.$4K
- Bard Peripheral Vascular, Inc.$2K
- Silk Road Medical, Inc.$2K
- Cook Medical LLC$2K
- plus $6K from 32 others
What the payments were for
- Speaking & faculty fees$230%
- Travel & lodging$3,64515%
- Food & beverage$20,48982%
- Other$9654%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 86 | $5,407 |
| Endologix LLC | 29 | $4,380 |
| Penumbra, Inc. | 75 | $4,192 |
| Bard Peripheral Vascular, Inc. | 41 | $2,211 |
| Silk Road Medical, Inc. | 37 | $1,593 |
| Cook Medical LLC | 58 | $1,527 |
| Integra Lifesciences Corporation | 11 | $1,256 |
| Acera Surgical, Inc. | 13 | $694 |
| Medtronic(2 entities) | 19 | $615 |
| Boston Scientific | 8 | $431 |
| Angiodynamics, Inc. | 7 | $351 |
| Lemaitre Vascular, Inc. | 9 | $302 |
| Abbott | 5 | $267 |
| Shockwave Medical, Inc | 3 | $225 |
| BD | 2 | $185 |
| Johnson & Johnson(2 entities) | 12 | $181 |
| Inari Medical, Inc. | 4 | $159 |
| Nevro Corp. | 2 | $157 |
| Stryker | 6 | $132 |
| Artivion, Inc. | 1 | $107 |
| Edwards Lifesciences | 1 | $91 |
| Baxter Healthcare | 1 | $91 |
| Cardiva Medical, Inc. | 3 | $72 |
| Smith+Nephew | 3 | $70 |
| Amgen | 4 | $64 |
| Bolton Medical Inc | 1 | $51 |
| Asahi Intecc USA, Inc. | 2 | $51 |
| Polynovo North America LLC | 2 | $44 |
| Kerecis Limited | 1 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Innovation Technologies Inc | 1 | $24 |
| Organogenesis Inc. | 1 | $23 |
| Getinge USA Sales, LLC | 1 | $22 |
| Pfizer | 1 | $20 |
| Sanara Medtech Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
| Biocompatibles, Inc. | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE TAG Thoracic Branch Endoprosthesis$1,707
- Indigo$1,673
- Torus Stent Graft System$1,342
- ENDOCROSS Device$1,342
- INTEGRA$1,024
- ENROUTE Transcarotid Neuroprotection System$938
- Penumbra Ruby Coil$854
- ENHANCE Transcarotid Peripheral Access Kit$629
- Alto Abdominal Stent Graft System$574
- Indigo System$544
- GORE TAG Thoracic Endoprosthesis$511
- ENROUTE Transcarotid Stent System$504
- ENROUTE 0.014 Guidewire$504
- Restrata Wound Matrix$480
- ENROUTE Transcarotid Stent$434
- ACell$375
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$361
- RotarexS 6 F x 135 cm$338
- Pristine$306
- Lutonix Drug Coated Balloon$305
How this compares
$25,121 in reported general payments places this provider in the 80th percentile of 35 vascular surgery providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 44 | $34,090 |
| EliquisApixaban | 20 | $11,370 |
| ClopidogrelClopidogrel Bisulfate | 97 | $593 |
| Atorvastatin Calcium | 13 | $3 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $181 | $34,09044 claims |
| PfizerEliquis | $20 | $11,37020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 35 vascular surgery providers in Nebraska.
Other vascular surgery in Omaha
- John ParkOmaha$616K
- Iraklis PipinosOmaha$120K
- David VogelOmaha$41K
- Marcus BaltersOmaha$27K
- Rao GuttaOmaha$27K
- Gernon LongoOmaha$23K
- Yue GaoOmaha$14K
- Tammy RamosOmaha$10K
- Jason CookOmaha$7K
- Katherine BrownOmaha$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.